Skip to main content
Buy Wolverine

Questions readers actually ask

Questions.

Plain-language answers to the questions that come up most often about the BPC-157 + TB-500 research blend, with citations back to the underlying studies.

What is the BPC-157 + TB-500 research blend?

It is a combination of two synthetic peptides — BPC-157, a 15-amino-acid pentadecapeptide modeled on a cytoprotective fragment of a protein found in human gastric juice [1], and TB-500, a synthetic 7-amino-acid fragment (Ac-LKKTETQ-OH) derived from the central actin-binding helix of thymosin beta-4 [22]. Research-peptide vendors and forums sometimes co-package or co-administer them under the informal nickname Wolverine, on the rationale that the two peptides act through complementary pathways: BPC-157 contributes a local angiogenic and cytoprotective signal at injury sites, while the TB-500 fragment contributes an intracellular actin-sequestration signal supporting cell migration [16]. No peer-reviewed controlled combination study has been published [6][16].

Why are BPC-157 and TB-500 combined in the Wolverine blend?

The mechanistic rationale is that the two peptides target different but complementary parts of the tissue-repair process. BPC-157 acts locally at injury sites, where it upregulates VEGFR2-PI3K-Akt-eNOS angiogenic signaling, modulates nitric oxide synthase activity, and shifts macrophages toward an anti-inflammatory M2 phenotype [4][19]. TB-500 / Tβ4 acts intracellularly, with its LKKTETQ helix binding monomeric G-actin in 1:1 stoichiometry and freeing the cytoskeletal machinery that drives cell migration and progenitor mobilization [22]. The argument is structural complementarity. The argument has not, however, been tested in a peer-reviewed controlled study of the combination at defined doses [6][16].

Is TB-500 the same molecule as thymosin beta-4?

No, and the distinction matters. Full-length thymosin beta-4 (Tβ4) is a 43-amino-acid peptide naturally found in mammalian cells. TB-500, as sold by research-chemical suppliers, is a synthetic 7-amino-acid N-acetylated fragment (Ac-LKKTETQ-OH) corresponding to residues 17 to 23 of Tβ4 [22]. The fragment retains the central actin-binding helix of the parent peptide, but it lacks the rest of the chain.

The practical consequence: the overwhelming majority of clinical efficacy data attributed to TB-500 in marketing copy was actually generated with the full-length 43-residue peptide — the RegeneRx and HLB Therapeutics ophthalmic programs (RGN-259) [13][14], the venous-stasis-ulcer Phase II [12], the Bock-Marquette cardiac papers [9][10], the 2021 NL005 first-in-human Phase I [15]. Head-to-head clinical equivalence of the 7-mer fragment with the full-length peptide has not been formally demonstrated [16].

How do BPC-157 and TB-500 work mechanistically?

BPC-157 acts at the injury site by promoting angiogenesis through the VEGFR2-PI3K-Akt-eNOS axis, modulating the nitric oxide system, activating ERK1/2 MAPK and the FAK-paxillin pathway in fibroblasts, upregulating the growth-hormone receptor in tendon fibroblasts via JAK2 [2], and shifting macrophages toward an anti-inflammatory M2 phenotype [4][19].

TB-500 / Tβ4 acts inside the cell. Its LKKTETQ helix binds G-actin in 1:1 stoichiometry, sequestering 40 to 50 percent of the cellular monomeric actin pool and regulating actin-filament dynamics that drive cell migration [22]. In the full-length-peptide context, this sequestration is the basis for integrin-linked-kinase activation in cardiomyocytes [9], mobilization of epicardial progenitor cells in adult mouse hearts [10], and oligodendrocyte progenitor differentiation after embolic stroke via p38 MAPK [17].

What does the research literature say about combining BPC-157 and TB-500?

The mechanism is plausible. The data are not. No peer-reviewed controlled head-to-head or combination preclinical study has been published that defines a synergy ratio, a combined dose, or a primary endpoint for BPC-157 paired with TB-500 (or with full-length Tβ4) [6][16]. The 2025 narrative review in Current Reviews in Musculoskeletal Medicine notes this explicitly; the 2025 HSS systematic review of BPC-157 makes the same point [7]. Combination claims that circulate in vendor and forum copy are extrapolations from each peptide's independently characterized mechanisms — not findings from a controlled study of the pair.

Is there any peer-reviewed clinical trial on the BPC-157 + TB-500 combination?

No. There is no peer-reviewed clinical trial of the BPC-157 + TB-500 combination as of mid-2025 [6][16]. ClinicalTrials.gov lists no active or completed registration for the pairing. The individual components have their own (limited) clinical record: BPC-157 has three small uncontrolled human reports, all from a single investigator group [6]; full-length thymosin beta-4 has Phase I through Phase III data in ophthalmic, dermal, and cardiac indications [12][13][14][15]. The combination has not been formally studied in humans.

What is the WADA status of BPC-157 and TB-500?

Both are prohibited at all times, in and out of competition. BPC-157 is listed under category S0 (Non-Approved Substances) of the WADA Prohibited List, explicitly named on the 2022 list (effective 1 January 2022) and on every annual list since. TB-500 and synthetic thymosin beta-4 derivatives are listed under category S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). A 2024 Canadian Centre for Ethics in Sport case produced a four-year ineligibility for an athlete who had used the BPC-157 + TB-500 combination. An athlete subject to anti-doping rules should not use either compound.

What is the FDA position on BPC-157 and TB-500?

Neither compound is approved by the FDA for any human indication. In September 2023, the FDA placed both BPC-157 and thymosin beta-4 / TB-500 on its Category 2 list of 503A bulk drug substances — the list of substances that may present significant safety risks and that may not be used in pharmacy compounding for human use [7]. Both compounds remain available through laboratory-supply channels for research use, but neither qualifies as a dietary supplement, food additive, or approved drug under U.S. federal regulation.

What doses of BPC-157 and TB-500 appear in the research literature?

BPC-157 has been studied most commonly at 10 μg/kg or 10 ng/kg in rodent injury models, given intraperitoneally, intragastrically, or in drinking water [1][3][4][8]. Higher doses (20 to 200 μg/kg intraperitoneally) appear in specific contexts such as ischemia-reperfusion and spinal cord injury [20][26]. Human BPC-157 reports have used 10 mg intravesicularly and up to 20 mg intravenously [6].

TB-500 / Tβ4 preclinical doses range from 0.5 to 12 mg/kg intraperitoneally in stroke and dermal models [17]. Human full-length Tβ4 Phase I used 0.05 to 25 μg/kg as a single IV dose and 0.5 to 5 μg/kg/day for 10 days [15]. Topical Phase II and Phase III ophthalmic programs used 0.01 to 0.1 percent solutions dosed up to six times daily [13][14].

None of these figures are a dosing recommendation. The dose section on the dosage page treats them as research context, not as a protocol.

What does Phase II/III data look like for thymosin beta-4 in wound healing and the eye?

The full-length Tβ4 record is the most developed clinical dataset relevant to the TB-500 fragment. In severe dry eye disease, a 56-day double-masked Phase II of 0.1% RGN-259 ophthalmic solution reported a 35.1% reduction in ocular discomfort and a 59.1% reduction in total corneal fluorescein staining versus vehicle at day 56 [13]. In neurotrophic keratopathy, a randomized Phase III of 0.1% RGN-259 reported positive healing and comfort endpoints; the subsequent commercial Phase III (SEER-3) missed its primary endpoint [14]. In venous stasis ulcers, a 72-patient multi-center European Phase II of topical Tβ4 reported an approximately one-month acceleration of complete wound closure in completers across the active arms [12]. Dermal Phase II programs in pressure ulcers and epidermolysis bullosa reported acceleration of repair in completer subsets [16].

Why is the blend nicknamed Wolverine in the research community?

Wolverine is research-community vernacular for the rapid-healing phenotype that some forum users associate with the BPC-157 + TB-500 pairing. It is not a brand, not a trademark we have any license to use, and not a reference to any character or franchise. We treat it as a folk-category name — useful as a search term, not useful as a description of the underlying biology. The body-copy descriptor throughout this site is BPC-157 + TB-500 research blend.